HIV Drug Resistance can Be Identified by Genome Sequencing
s a member of the Roche group. Ultra Deep Sequencing provides an esse...Kozal said that current genotypic resistance technology availabl...This study clearly shows that resistance HIV strains present at ...It is estimated that 22 million people have died from AIDS and over......
s, a member of the Roche group. Ultra Deep Sequencing provides an essential tool for research on viral diseases and their treatments. The ability to use 454 Sequencing to detect rare viral mutations is a crucial research tool to better understand the early stages of HIV drug resistance.
Kozal said that current genotypic resistance technology available to clinicians is limited to detecting resistance mutations that are present at levels of approximately 20 percent or greater in the circulating viral population in a patient. Therefore, the current technology used in the clinic may miss many low-level resistant HIV strains that can grow rapidly under drug selection pressure and lead to therapy failure.
This study clearly shows that resistance HIV strains present at the one percent level can lead to premature failure of therapy, said Kozal. It is our hope that in the future, clinicians can use this knowledge to better choose antiretroviral drug combinations that have the ability to suppress these resistant HIV strains, leading to better clinical responses in patients.
It is estimated that 22 million people have died from AIDS and over 42 million people are living with HIV/AIDS worldwide. In the U.S. alone, 40,000 new infections occur each year.